Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Novartis Ag (NVSEF) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Novartis Ag (NVSEF) over the last 17 years, with Q4 2025 value amounting to -$304.0 million.

  • Novartis Ag's Interest Expenses fell 1054.55% to -$304.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.1 billion, marking a year-over-year decrease of 1371.77%. This contributed to the annual value of -$1.1 billion for FY2025, which is 1371.77% down from last year.
  • Novartis Ag's Interest Expenses amounted to -$304.0 million in Q4 2025, which was down 1054.55% from -$281.0 million recorded in Q3 2025.
  • Novartis Ag's Interest Expenses' 5-year high stood at -$200.0 million during Q1 2023, with a 5-year trough of -$304.0 million in Q4 2025.
  • Moreover, its 5-year median value for Interest Expenses was -$216.5 million (2023), whereas its average is -$231.6 million.
  • Per our database at Business Quant, Novartis Ag's Interest Expenses surged by 1548.12% in 2021 and then plummeted by 2672.81% in 2024.
  • Quarter analysis of 5 years shows Novartis Ag's Interest Expenses stood at -$206.0 million in 2021, then decreased by 0.49% to -$207.0 million in 2022, then dropped by 4.83% to -$217.0 million in 2023, then decreased by 26.73% to -$275.0 million in 2024, then decreased by 10.55% to -$304.0 million in 2025.
  • Its Interest Expenses was -$304.0 million in Q4 2025, compared to -$281.0 million in Q3 2025 and -$289.0 million in Q2 2025.